Epigenomics AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: August 15, 2019
Pages: 50
US$ 499.00
Epigenomics AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Epigenomics AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Epigenomics AG Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Epigenomics AG and its competitors. This provides our Clients with a clear understanding of Epigenomics AG position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Epigenomics AG that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Epigenomics AG. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Epigenomics AG financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Epigenomics AG competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Epigenomics AG business.

About Epigenomics AG

Epigenomics AG, a molecular diagnostics company, engages in the development of screening, monitoring, and classification tests for cancer. It also develops drug response (pharmacodiagnostic) tests for cancer. All of the tests are based on DNA methylation analysis. The company primarily operates in Germany, the United States of America, and France.

The company engages in the development and marketing of procedures and devices for the production of particular epigenetic parameters, such as DNA methylation patterns, as well as the information technology basis necessary for the procurement and evaluation. The company’s primary focus is on the development of novel diagnostic products for cancer.

The company operates two strategic business units (SBUs): Diagnostics and Pharma Technology.


The company’s Diagnostics business unit develops pure diagnostic tests for the early detection, classification and monitoring of cancer and commercializes these through in-vitro diagnostic partnerships.

In its Diagnostics business unit, the company is developing three types of products for the diagnosis of cancer: blood-based early detection tests; blood-based monitoring tests; and tissue-based molecular classification tests.

The product development pipelines consists of early detection tests for each of colon, prostate, and breast cancers, as well as a molecular classification tests for aggressive versus non-aggressive prostate cancer. All of these drugs are developed in collaboration with the R&D and commercialization partner Roche Duagbistucs. The company is developing cancer indications, as well as tests in other cancers, such as lung, bladder, liver, ovarian, etc.

Pharma Technology

The company’s Pharma Technology business unit focuses on programs that are geared towards developing companion tests for specific cancer drugs and assisting partnering pharmaceutical and biotech companies in their respective drug development programs. The company develops tests for the pharmaceutical and biotech industry to support the clinical development and the marketing of drugs.

The company, through its Pharma Technology business unit, develops products, such as Brest Cancer (Tamoxifen) Treatment response test and other cancer treatment response biomarker studies with pharma companies. The company’s most improved product is the Roche breast cancer treatment response test, which has undergone two years of extensive discovery.

The company would add other pharmacodiagnostic test types to its development pipelines, such as developing tests to major marketed cancer drugs on its own, as well as partnered programs with drug developing companies.


Epigenomics AG has entered into a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott Molecular. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin 9. The agreement also contains provisions for the evaluation by Abbott of some of Epigenomics' other proprietary biomarkers for additional cancer indications.

Epigenomics AG has entered into an agreement for a research and development co-operation with Centocor, Inc. Epigenomics would develop and analyse biomarkers for Centocor, which engages in treatments for immune-related diseases, such as cancer and immune-mediated inflammatory disorders.

The company has entered into R&D collaboration with the Myriad Genetics Inc. to identify and analyze DNA methylation biomarkers that may predict patients' response to an undisclosed marketed oncology drug. Under the terms of the deal, Epigenomics would use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling on samples provided by Myriad.

Significant Events

Sysmex Corp. and Epigenomics AG have a strategic research and development collaboration agreement in molecular diagnostics. Under the terms of the agreement, Sysmex and Epigenomics would assess the suitability of Sysmex' molecular diagnostics instrumentation for the detection of DNA methylation cancer biomarkers in blood.


Epigenomics AG was founded in 1998.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Epigenomics AG Direct Competitors
5.2. Comparison of Epigenomics AG and Direct Competitors Financial Ratios
5.3. Comparison of Epigenomics AG and Direct Competitors Stock Charts
5.4. Epigenomics AG Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Epigenomics AG Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Epigenomics AG Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Epigenomics AG Key Executives
Key Executives Biographies1
Key Executives Compensations1
Epigenomics AG Major Shareholders
Epigenomics AG History
Epigenomics AG Products
Revenues by Segment
Revenues by Region
Epigenomics AG Offices and Representations
Epigenomics AG SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Epigenomics AG Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Epigenomics AG Capital Market Snapshot
Epigenomics AG Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Epigenomics AG Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Epigenomics AG Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Epigenomics AG Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Epigenomics AG 1-year Stock Charts
Epigenomics AG 5-year Stock Charts
Epigenomics AG vs. Main Indexes 1-year Stock Chart
Epigenomics AG vs. Direct Competitors 1-year Stock Charts
Epigenomics AG Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Epigenomics AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: